sec filing
SN
NASDAQ · SNSE
Sensei Biotherapeutics, Inc.
Healthcare · Biotechnology
$13.85
Down-$3.97 (-22.28%)
Updated Sep 16, 2026, 8:39 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.16M
- P/E ratio
- -0.46
- Dividend yield
- 0.00%
- 52-week range
- $5.60 – $36.76
- Volume
- 219.75K
- Avg. volume
- 65.9K
Price performance
SNSE price history
1M range · 0 trading sessions · Daily adjusted prices
SNSE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SNSE news
The latest Smart Investors Daily articles mentioning SNSE.
Stock researchCompany · Overview
SNSE research
Overview
Company profile and research snapshot.
Company profile
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 15, 2026 | BTIG | Buy | — |
| Jun 11, 2026 | BTIG | Buy | — |
| May 29, 2026 | Cantor Fitzgerald | Overweight | — |
| May 28, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| May 22, 2026 | Citigroup | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.